New Approach for Potential Treatment of Liver Cancer Patients with Hep B Virus Infection

Workflow of how: 1) eligible patients and the appropriate HBV-specific T cells are selected and 2) T cells are engineered, for T cell therapy of HBV-HCC.

Researchers from Duke-NUS Medical School, Singapore General Hospital (SGH) and Lion TCR have demonstrated that they were able to engineer HBV-specific T cells, a type of immune cells found in the body, to treat Hepatocellular carcinoma (HCC), a commonly occurring liver cancer. The treatment was also individualized, as T cells that were engineered were specific to the patients. The approach was successfully performed on two liver transplanted patients who had HBV associated liver cancer recurrence with one patient seeing a reduction in size of the tumor lesions.

Chronic hepatitis B virus (HBV) infection is predominant in Asia and is highly associated with the development of Hepatocellular carcinoma (HCC), the commonly occurring liver cancer. The currently effective treatments for small to moderate size HCC are restricted to surgery, liver transplantation and loco-regional treatment that kill cancer cells by interventional radiologic means, while treatment with drugs helps only in a modest increase in the overall survival in more extensive disease. In patients who have HCC recurrence after liver transplantation, the treatment options are even more limited.

“In this study we showed that the integrated HBV-DNA gene components in the HCC cells were able to activate functional HBV-specific T cells. Hence, by analyzing the specific HBV- DNA integration patterns in these HCC cells, we were able to select, design and engineer the individualiZed T cells for therapy. Our studies showed that these engineered T cells were able to destroy the tumor,” said Dr Antonio Bertoletti, Professor of the Emerging Infectious Diseases (EID) Program at Duke-NUS, Founder of the Singapore biotech company Lion TCR and co- author of the study.

“There were over 20 T cell infusions that were successfully performed on the two liver- transplanted patients. None of the patients experienced adverse reactions related to the treatment and one of them had a reduction in the tumor size of distant metastases of the liver cancer. Given that 80 per cent of the HCC cases in Asia are currently HBV-related, this approach could lead to a major breakthrough in improving the survival and quality of life of patients suffering from this disease,” said Dr Thinesh Lee Krishnamoorthy, Consultant, Department of Gastroenterology and Hepatology, SGH, and co-author of this study.

The authors plan to further refine the technique and treatment strategy with further research study and trials to improve the efficacy of the therapy.

1 Comment
  1. Thanks to Robinson buckler who cured me of hepatitis B, I was diagnosed of hepatitis b virus two years ago, the agony of living with these virus was tough, because of what i head concerning the virus , I was having a serious pain i went for another check the dr said the virus was strong in blood and has developed to chronic hepatitis b it may start eating up my liver, i concluded that i was going to die, may Almighty Allah be praised i came across some persons testifying about Robinson buckler how they were cure totally from chronic hepatitis b virus, I decide to contact Robinson buckler, he told me i will be fine within 6 weeks, but i took it as a form of encouragement because i did not believe i can be cure from this nightmare, meanwhile i order for the medication within 5 weeks of using the medication my eyes that was yellow become normal and the pain was gone to say the least i went for another check up behold it was negative hepatitis b was gone totally, I am supper excited. Don’t be deceived there is cure to hepatitis b but the cure is rare. If you have the same or other infection you can contact…………………………{{{{ Robinsonbuckler@hotmail. co m }}}},

Leave a Reply

Your email address will not be published.

©2020. Global Health News Wire. Use Our Intel. All Rights Reserved. Washington, D.C.